Lingguizhugan Decoction Improved Obesity by Modulating the Gut Microbiota and its Metabolites in Mice

Title:Lingguizhugan Decoction Improved Obesity by Modulating the Gut Microbiota and its Metabolites in Mice

Volume: 25 Issue: 4

Author(s): Meiling Wang, Hairong Li, Chunmei Liu, Yuanyuan Zhang, Qian Wu and Yubin Yang*

Affiliation:

• Traditional Chinese Medicine Department, West China Second University Hospital, Sichuan University, Chengdu, China
• Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China

Keywords: Lingguizhugan decoction, gut microbiota, obesity, Traditional Chinese Medicine (TCM), metagenomics, metabolomics.

Abstract:

Background: The global obese population is rapidly increasing, urgently requiring the development of effective and safe weight-loss medications. The classic Chinese medicine formulation Lingguizhugan Decoction has exerted a significant anti-obesity effect. However, the underlying mechanism is still unclear.

Objective: This study aimed to explore the mechanism of LGZGD in the treatment of obesity based on the gut microbiota and its metabolites.

Methods: Three different dosages of LGZGD were gavaged to ob/ob mice for 8 weeks. Body mass and visceral fat mass were evaluated. Additionally, the changes in gut microbiota, fecal and plasma metabolites in mice after LGZGD treatment were analyzed by metagenomics and non-targeted metabolomics.

Results: The results demonstrated a significant anti-obesity effect of LGZGD treatment in ob/ob mice. Furthermore, the metagenomic analysis revealed that LGZGD reduced the ratio of Firmicutes / Bacteroidetes (F to B) in the gut, restored gut microbiota diversity, and identified 3 enriched KEGG pathways, including energy metabolism, lipid metabolism, and energy production and conversion pathways. Based on non-targeted metabolomics analysis, 20 key metabolites in the feces and 30 key metabolites in the plasma responding to LGZGD treatment were identified, and the levels of Eicosapentaenoic acid (EPA) and Myristoleic acid (MA) might be the metabolites related to gut microbiota after LGZGD treatment. Their biological functions were mainly related to the metabolism pathway.

Conclusions: These findings suggested that LGZGD had therapeutic potential for obesity. The mechanism of LGZGD alleviating obesity was associated with improving dysbiosis of the gut microbiota. LDZGD affected gut microbiota-derived metabolites of EPA and MA and may act on energy metabolism pathways.

Cite this article as:

Wang Meiling, Li Hairong, Liu Chunmei, Zhang Yuanyuan, Wu Qian and Yang Yubin*, Lingguizhugan Decoction Improved Obesity by Modulating the Gut Microbiota and its Metabolites in Mice, Current Drug Metabolism 2024; 25 (4) . https://dx.doi.org/10.2174/0113892002289388240705113755